Opthea Ltd
opthea.comWhat Do They Do?
Plans to reformulate experimental medicines targeting blood-vessel growth proteins for possible use in diseases beyond the eye.
20-F for FY2025, filed Sep 15, 2025
Who Are Their Customers?
Third-party licensees use intellectual property unrelated to the company’s drug-development program, primarily for research. The company earns royalty income from customers based outside Australia.
20-F for FY2025, filed Sep 15, 2025The Group’s only revenue stream in the current and previous financial year is royalty income generated from licenses granted in respect of…View ↗
How Are They Changing?
From eye trials to other diseases
The earlier report focused on developing an eye treatment for wet age-related macular degeneration, with possible use in other retinal diseases. The latest report says that program has ended and the company is reformulating drug candidates for possible use in diseases in other organs.
20-F for FY2022, filed Sep 29, 2022 20-F for FY2025, filed Sep 15, 2025
Loading...
